The IPO Buzz: Generate Biomedicines (GENB Proposed) Launches $400 Million IPO
Generate Biomedicines, Inc. (GENB Proposed), a clinical biology company developing a treatment for severe asthma, launched its $400 million IPO early today – Monday, Feb. 23, 2026 – for pricing later this week. (Please see the IPO Calendar for the pricing date.) In its S-1/A filing, Generate Biomedicines disclosed the IPO’s terms – 25 million shares at a price range of $15.00 to $17.00 to..
Read more February 23, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| ClearThink 1 Acquisition Corp. | CTAAU | 15.0 | $ 150.0 mil | 2/24/2026 Tuesday | S/O | S/O |
| AIGO Holding Ltd. | AIGO | 2.0 | $ 10.0 mil | 2/25/2026 Week of | S/O | S/O |
| Generate Biomedicines | GENB | 25.0 | $ 400.0 mil | 2/27/2026 Friday | S/O | S/O |
Last 100 IPOs - February 22, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 54 |
| Number Down: | 40 |
| Number Unchanged: | 6 |
| Percentage Change From Issue Price: | -2.85% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - February 22, 2026
| Number of IPOs priced (Excluding 43 units) : | 27 |
| Number Up: | 15 |
| Number Down: | 9 |
| Number Unchanged: | 3 |
| Total Return From Issue Price: | 7.94% |
| The Nasdaq Composite Index YTD % Change | 35.22% |